Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
RYTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.17 - $68.58
Previous CloseN/A
Volume91.33K
Average Volume (3M)803.09K
Market Cap
$3.76B
Enterprise Value$3.38B
Total Cash (Recent Filing)-$241.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.20
Next Earnings
May 06, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding63,223,730
10 Day Avg. Volume1,320,167
30 Day Avg. Volume803,092
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.28
Price to Cash Flow (P/CF)-43.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.98
Enterprise Value/Ebitda-14.18
Forecast
1Y Price Target
$79.25Price Target Upside23.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe commercial expansion into HO is seen as an upside opportunity, with a well-identified patient population and potential for a strong launch trajectory.
Regulatory ApprovalManagement expects a priority review for the sNDA filing without the need for an advisory committee, indicating confidence in the approval process.
Bears Say
Growth ChallengesThe expectation for linear growth in the BBS launch highlights the challenges in patient identification and diagnosis, indicating slower growth.
Side EffectsConcerns were raised about the severity of GI side effects and their impact on the effectiveness of anti-seizure medications and other oral medications.
---
Ownership Overview
0.63% Insiders
26.59% Mutual Funds
0.38% Other Institutional Investors
60.64% Public Companies and
Individual Investors
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $35.17 and its highest was $68.58 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $3.76B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is May 06, 2025 which is in 7 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Feb 26, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.694 by -$0.026.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.69.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 63,223,730 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.694. Following the earnings report the stock price went up 4.488%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
---
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.25 (23.04% Upside)
$79.25 (23.04% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.12%
12-Months-Change
Fundamentals
Return on Equity
-272.15%
Trailing 12-Months
Asset Growth
18.25%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
---
RYTM Company Deck
---
RYTM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong financial positioning, robust sales growth, and significant pipeline advancements. However, there are concerns about high operating expenses and potential challenges in market uptake for new indications.Read More>---
RYTM Stock 12 Month Forecast
Average Price Target
$79.25
▲(23.04% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crispr Therapeutics AG
―
Akero Therapeutics
―
Springworks Therapeutics
―
Avidity Biosciences
―
---